Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Yagi, Takuya ^a   Kosakai, Arifumi ^a   Ito, Daisuke ^a   Okada, Yohei ^a   Akamatsu, Wado ^a   Nihei, Yoshihiro ^a   Nabetani, Akira ^b   Ishikawa, Fuyuki ^b   Arai, Yasumichi ^a   Hirose, Nobuyoshi ^a   Okano, Hideyuki ^a   Suzuki, Norihiro ^a  

^a KEIO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PEPTIDES AND PROTEINS; PROTEIN LIN28; PROTEIN PARK4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

AGED; ALPHA SYNUCLEIN GENE; ARTICLE; CADAVER; CELL DIFFERENTIATION; CENTENARIAN; CONTROLLED STUDY; DEGENERATIVE DISEASE; DONOR; EMBRYO; ETHNIC GROUP; FEMALE; FIBROBLAST; GENE; GENE NUMBER; GENE TRIPLICATION; HEMISPHERE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; LIN28 GENE; LONGEVITY; NANOG GENE; NERVE CELL; NEUROSPHERE; OCT4 GENE; ONSET AGE; PARKINSON DISEASE; PATHOGENESIS; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; SOX2 GENE;

AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEWY BODY DISEASE; MALE; NEURONS; PARKINSON DISEASE; TRANSCRIPTION FACTORS;

EID: 84864330048     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041572     Document Type: Article

References (31)

1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
2. Takahashi K, Yamanaka S, (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
3. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, et al. (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8: 267-280.
4. Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, et al. (2011) Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. Nat Commun 2: 440.
5. Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, et al. (2011) Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J Neurosci 31: 5970-5976.
6. Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, et al. (2011) Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet.
7. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, et al. (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature.
8. Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, et al. (2012) Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun 3: 668.
9. Editorial NG, (2011) Supersequencing the supercontrols. Nat Genet 43: 1041.
10. Lapasset L, Milhavet O, Prieur A, Besnard E, Babled A, et al. (2011) Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev 25: 2248-2253.
11. Nori S, Okada Y, Yasuda A, Tsuji O, Takahashi Y, et al. (2011) Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci U S A 108: 16825-16830.
12. Okada Y, Matsumoto A, Shimazaki T, Enoki R, Koizumi A, et al. (2008) Spatiotemporal recapitulation of central nervous system development by murine embryonic stem cell-derived neural stem/progenitor cells. Stem Cells 26: 3086-3098.
13. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, et al. (2009) Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 27: 743-745.
14. Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, et al. (2011) Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature.
15. Li H, Collado M, Villasante A, Strati K, Ortega S, et al. (2009) The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460: 1136-1139.
16. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, et al. (2009) Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460: 1140-1144.
17. Marion RM, Strati K, Li H, Tejera A, Schoeftner S, et al. (2009) Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 4: 141-154.
18. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, et al. (2009) Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460: 1145-1148.
19. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, et al. (2009) Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev 23: 2134-2139.
20. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
21. Maestre G, Ottman R, Stern Y, Gurland B, Chun M, et al. (1995) Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 37: 254-259.
22. Myers RH, Schaefer EJ, Wilson PW, D'Agostino R, Ordovas JM, et al. (1996) Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology 46: 673-677.
23. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, et al. (1993) Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 342: 710-711.
24. Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, et al. (1994) Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 6: 29-32.
25. Ewbank DC, (2002) Mortality differences by APOE genotype estimated from demographic synthesis. Genet Epidemiol 22: 146-155.
26. Sebastiani P, Solovieff N, Puca A, Hartley SW, Melista E, et al. (2010) Genetic signatures of exceptional longevity in humans. Science 2010.
27. Flachsbart F, Caliebe A, Kleindorp R, Blanche H, von Eller-Eberstein H, et al. (2009) Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci U S A 106: 2700-2705.
28. Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, et al. (2003) Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290: 2030-2040.
29. Sebastiani P, Montano M, Puca A, Solovieff N, Kojima T, et al. (2009) RNA editing genes associated with extreme old age in humans and with lifespan in C. elegans. PLoS One 4: e8210.
30. Ito D, Seki M, Tsunoda Y, Uchiyama H, Suzuki N, (2010) Nuclear transport impairment of ALS-linked mutations in FUS/TLS. Ann Neurol 69: 152-162.
31. Zhang DH, Zhou B, Huang Y, Xu LX, Zhou JQ, (2006) The human Pif1 helicase, a potential Escherichia coli RecD homologue, inhibits telomerase activity. Nucleic Acids Res 34: 1393-1404.